세계의 성장호르몬 결핍증 시장 규모, 점유율, 성장 분석 : 유형별, 진단별, 치료별, 투여 경로별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)

Growth Hormone Deficiency Market size was valued at USD 3.7 billion in 2023 and is poised to grow from USD 3.9 billion in 2024 to USD 5.99 billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).

The rising incidence of growth hormone deficiency (GHD), driven by factors like genetic disorders, brain injuries, and specific medical treatments, is significantly boosting the demand for growth hormone therapies. Data from the National Center for Biotechnology Information (NCBI) indicates that approximately 1 in every 3,500-4,000 children in the UK is affected by pediatric GHD, highlighting a growing need for effective treatments. This increasing prevalence is catalyzing industry expansion, with robust research and development at the forefront. A notable advancement occurred in February 2022 when Pfizer and OPKO received European Union marketing authorization for their Once-Weekly NGENLA(TM) (somatrogon) Injection, marking an important milestone in the growth hormone therapy landscape and further cementing the industry's growth trajectory.

Top-down and bottom-up approaches were used to estimate and validate the size of the Growth Hormone Deficiency market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Growth Hormone Deficiency Market Segments Analysis

Global Growth Hormone Deficiency Market is segmented by Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel and region. Based on Type, the market is segmented into Pediatric Growth Hormone Deficiency and Adult Growth Hormone Deficiency. Based on Diagnosis, the market is segmented into Blood Tests, Imaging Tests, Computerized tomography (CT) scans, Magnetic resonance imaging (MRI) and Others. Based on Treatment, the market is segmented into Pharmacological Therapy, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts, and Surgery. Based on Route of Administration, the market is segmented into Intravenous, Intramuscular and Others. Based on End User, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Growth Hormone Deficiency Market

One of the key market drivers for the global growth hormone deficiency market is the increasing prevalence of growth hormone deficiency and related disorders among children and adults. This rise is partly attributed to better diagnosis and awareness, leading to earlier identification and treatment. Additionally, lifestyle factors, such as sedentary habits and rising obesity rates, contribute to hormonal imbalances, further fueling the need for growth hormone therapies. As healthcare providers continue to emphasize the importance of addressing growth issues and improving quality of life, the demand for effective growth hormone treatments is expected to grow significantly in the coming years.

Restraints in the Growth Hormone Deficiency Market

The market for Growth Hormone Deficiency faces significant restraints, primarily due to the high costs associated with Human Growth Hormone (HGH) therapy. This financial burden limits accessibility for various patient groups and places considerable strain on healthcare systems. A 2022 medical journal study highlighted the extensive financial challenges faced by patients and healthcare providers alike, emphasizing the need for more affordable treatment options. Addressing these economic hurdles is crucial for enhancing access to HGH therapy, prompting calls for the development of cost-effective solutions and pricing reforms to ensure that more individuals can benefit from necessary treatments without extreme financial hardship.

Market Trends of the Growth Hormone Deficiency Market

The Growth Hormone Deficiency (GHD) market is experiencing a noteworthy shift driven by innovative advancements in drug delivery systems. The introduction of wearable patches, needle-free devices, and autoinjectors enhances patient convenience and compliance, transforming how growth hormone therapies are administered. Additionally, the rise of long-acting formulations and implantable devices allows for extended-release options, significantly reducing the frequency of dosing. These innovations not only improve treatment efficacy but also elevate patient experiences, enabling wider accessibility to essential therapies. As the industry embraces these developments, the GHD market is set for robust growth, highlighting significant opportunities for pharmaceutical companies and healthcare providers alike.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis

Global Growth Hormone Deficiency Market Size by Type & CAGR (2025-2032)

• Market Overview
• Pediatric Growth Hormone Deficiency
• Adult Growth Hormone Deficiency

Global Growth Hormone Deficiency Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Blood Tests
• Imaging Tests
• Computerized tomography (CT) scans
• Magnetic resonance imaging (MRI)
• Others

Global Growth Hormone Deficiency Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Pharmacological Therapy
• Recombinant Human Growth Hormone
• Human Pituitary Gland Extracts
• Surgery

Global Growth Hormone Deficiency Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Intravenous
• Intramuscular
• Others

Global Growth Hormone Deficiency Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Growth Hormone Deficiency Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Growth Hormone Deficiency Market Size & CAGR (2025-2032)

• North America (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ascendis Pharma A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OPKO Health Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genexine, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LG Chem Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anhui Anke Biotechnology (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JCR Pharmaceuticals Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai United Cell Biotechnology Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hanmi Pharmaceutical Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Strongbridge Biopharma plc (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneScience Pharmaceuticals Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BIOCAD (Russia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Krka, d. d. (Slovenia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OPBIO Factory Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations